TOP - May 2017, Vol 10, No 2

An infusion-related reaction documentation tool and grading system and its integration into the electronic health record (EHR) is expected to better identify patients at risk for future reactions, and improve communication among oncology team members.
Immune-related toxicities in patients with NSCLC can be traced back to the mechanism of action of immune checkpoint inhibitors.
Patrick J. Medina, PharmD, BCOP, is Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa.
Although beneficence, autonomy, and justice comprise the bulwark of ethical principles in medicine, their prioritization has changed over the course of history.
In the May issue of The Oncology Pharmacist (TOP), we feature a conversation with Patrick J. Medina, PharmD, BCOP, Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa, in which he discusses changes to the reimbursement model, bridging the knowledge gap in a rapidly evolving field, and why provider status is the “holy grail” of pharmacy.
As pharmacists’ responsibilities extend beyond dispensing medications to include advanced patient-centered services, many already meet the definition of nonphysician provider under Medicare Part B, yet they are often not reimbursed for their services.
As options for second-line therapy for patients with metastatic renal-cell carcinoma continue to expand, so does the controversy surrounding optimal treatment selection.
When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small-cell lung cancer with measurable lesions.
Durability of benefit (ie, the possibility for sustained remission in patients with previously incurable disease) is already one of the hallmarks of immunotherapy. According to a recent statistical analysis, however, this durability even exceeded expectations.
By improving chemotherapy-induced peripheral neuropathy (CIPN), administration of duloxetine may enable patients with advanced pancreatic cancer to continue their treatment regimen of gemcitabine plus nab-paclitaxel.
Page 1 of 2
Results 1 - 10 of 17